03.11.2010 • NewsTeva PharmaceuticalsQ3 2010Ratiopharm

Teva Pharm Q3 Profit Up, Beats Forecast

Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, posted higher quarterly net profit that beat expectations, boosted by strong U.S. sales and its acquisition of Ratiopharm.

Third-quarter earnings per share excluding one-time items rose 46% to $1.30, Israel-based Teva said on Tuesday. Sales rose 20% to $4.25 billion.

Exchange rate differences negatively impacted sales in the quarter by $122 million compared with the third quarter of 2009. Analysts on average expected Teva to earn $1.27 a share on sales of $4.37 billion, according to Thomson Reuters I/B/E/S.

Teva completed its acquisition of German group Ratiopharm, whose results haven't been consolidated since August.

President and chief executive Shlomo Yanai said he expected to complete the integration of Ratiopharm ahead of schedule, "as we look forward to another year of continuous profitable growth."

Global sales of the company's multiple sclerosis treatment Copaxone rose 4% to a record $808 million. With a 30% market share Copaxone is the global market leader.

Teva declared a dividend of 0.7 shekels to be paid Dec. 2.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.